文献速递造血干细胞移植与细胞治疗

ICOS免疫PET可视化活化T细胞并早期诊断小鼠急性胃肠道移植物抗宿主病

ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD.
PubMed 文献 · Blood Adv · 2022-01-01

异基因造血细胞移植后急性移植物抗宿主病(GvHD)诊断依赖晚期临床和病理标准,亟需症状出现前的诊断策略。本研究在小鼠急性GvHD模型中,用锆-89-去铁胺-ICOS单克隆抗体PET示踪剂实现供者T细胞在肠道等靶组织活化的在体可视化,且不影响GvHD发病或移植物抗肿瘤效应,提示ICOS免疫PET是症状出现前早期诊断GvHD的有前景策略。

要点

  • ICOS被确定为GvHD期间活化T细胞免疫PET成像的潜在靶点。
  • 锆-89-去铁胺-ICOS PET示踪剂可在小鼠急性GvHD模型中在体显示肠道供者T细胞活化。
  • 该示踪剂不影响GvHD发病过程或移植的移植物抗肿瘤效应。

核心结论

  • 数据表明ICOS免疫PET是临床症状出现前早期诊断GvHD的有前景策略。

研究设计与样本

  • 在小鼠急性GvHD模型中评估锆-89-去铁胺-ICOS单克隆抗体PET示踪剂对供者T细胞活化的在体成像。

主要发现

  • 锆-89-去铁胺-ICOS单克隆抗体PET示踪剂可在体显示小鼠急性GvHD模型肠道等靶组织中供者T细胞活化。
  • 该示踪剂不影响GvHD发病过程或移植的移植物抗肿瘤效应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (HCT) is a well-established and potentially curative treatment for a broad range of hematological diseases, bone marrow failure states, and genetic disorders. Acute graft-versus-host disease (GvHD), mediated by donor T cells attacking host tissues, still represents a major cause of morbidity and mortality following allogeneic HCT. Current approaches to diagnosis of gastrointestinal acute GvHD rely on clinical and pathological criteria that manifest at late stages of disease. New strategies allowing for GvHD prediction and diagnosis, prior to symptom onset, are urgently needed. Noninvasive antibody-based positron emission tomography (PET) (immunoPET) imaging of T-cell activation post-allogeneic HCT is a promising strategy toward this goal. In this work, we identified inducible T-cell costimulator (ICOS) as a potential immunoPET target for imaging activated T cells during GvHD. We demonstrate that the use of the Zirconium-89-deferoxamine-ICOS monoclonal antibody PET tracer allows in vivo visualization of donor T-cell activation in target tissues, namely the intestinal tract, in a murine model of acute GvHD. Importantly, we demonstrate that the Zirconium-89-deferoxamine-ICOS monoclonal antibody PET tracer does not affect GvHD pathogenesis or the graft-versus-tumor (GvT) effect of the transplant procedure. Our data identify ICOS immunoPET as a promising strategy for early GvHD diagnosis prior to the appearance of clinical symptoms.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Xiao Z, Alam IS, Simonetta F, et al. ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD. Blood Adv. 2022. PMID: 35790103. doi:10.1182/bloodadvances.2022007403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。